X0306 4 2020-12-15 0 0001703057 AbCellera Biologics Inc. ABCL 0001834418 Lecault Veronique C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 V5Y 0A1 BRITISH COLUMBIA, CANADA 1 1 0 0 Chief Operating Officer Common Shares 2020-12-15 4 P 0 6000 20.00 A 1006000 D Common Shares 2020-12-15 4 P 0 17000 20.00 A 61580 I By spouse Common Shares 7155008 I See Footnote Common Shares 1273630 I See Footnote Stock Option (right to buy) 2.41 2020-10-29 4 A 0 2000000 0.00 A 2030-10-29 Common Shares 2000000 2000000 D Stock Option (right to buy) 20.00 2020-12-10 4 A 0 190800 0.00 A 2030-12-10 Common Shares 190800 190800 D These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein. These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein. On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00. 25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. /s/ Tryn Stimart, attorney-in-fact 2020-12-17